SEC Form 4 · accession 0001562180-19-000727
ARRAY BIOPHARMA INC · ARRY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Nicholas A Saccomano
Officer — CSO
Period of report
Jan 31, 2019
Accepted (ET)
Feb 4, 2019 · 4:28 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001100412
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 31, 2019 | M | 95,236 | $4.20 | A | 163,913 | D | |
| Common StockF1 | Jan 31, 2019 | F | 21,425 | $18.67 | D | 142,488 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $4.20 | Jan 31, 2019 | M | 95,236 | D | — | May 30, 2024 | Common Stock | 95,236 | 104,764 | D |
Explanation of responses
- F1Represents shares withheld to satisfy tax withholding obligations of the reporting person.
- F2The option vests in four equal annual installments beginning May 30, 2015.